Sarah Spencer
Investor Relations Kontakt bei VOR BIOPHARMA INC.
Profil
Sarah Spencer is currently the Head-Investor & Media at Vor Biopharma, Inc. She previously worked as a Media Relations Contact at GSK Plc and as the Vice President-Corporate Communications at Astellas Gene Therapies, Inc. from 2019 to 2021.
Ms. Spencer obtained an undergraduate degree from the State University of New York at Buffalo.
Aktive Positionen von Sarah Spencer
| Unternehmen | Position | Beginn |
|---|---|---|
| VOR BIOPHARMA INC. | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Sarah Spencer
| Unternehmen | Position | Ende |
|---|---|---|
| AUDENTES THERAPEUTICS, INC. | Public Communications Contact | 01.04.2021 |
| GSK PLC | Public Communications Contact | - |
Ausbildung von Sarah Spencer
| State University of New York at Buffalo | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GSK PLC | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
